Press Releases

  • 14 January 2021
    Regarding application for US regulatory clearance of hemostatic product (gastrointestinal endoscope area)
  • 17 July 2020
    Regarding Acquisition of Approval for Manufacturing and Sale of Hemostatic Products (TDM-621)
  • 16 July 2020
    Regarding Agreement Termination Notice Received from FUSO Pharmaceutical Industries, Ltd.
  • 12 May 2020
    Notification of FDA clearance for the extension of indications of our wound healing product PuraDerm in the United States
  • 14 April 2020
    Shared Research's report regarding the issue of stock acquisition rights and unsecured convertible bonds with stock acquisition rights announced by 3-D Matrix, Ltd.
  • 04 March 2020
    3-D Matrix Acquires a Patent in the U.S. for the New Self-Assembling Peptide Sequence for Tissue Occlusions.
  • 05 November 2019
    Notification of submission for the extension of indications of our wound healing product "PuraDerm" in the United States
  • 23 October 2019
    Notification regarding application for the manufacture and sales approval of the absorbable local hemostat (TDM- 621)
  • 30 September 2019
    Notice regarding Product Registration Obtained in Argentina (Absorbable Hemostat ❝TDM-621❞)
  • 05 September 2019
    Notice regarding the approval on an additional use of PuraStat in Australia:Post operative bleeding prevention
  • 26 July 2019
    Notice regarding the patent registration on a new boron formulation for Boron Neutron Capture Therapy (BNCT)
  • 22 July 2019
    Notification of completion of the recruitment for the clinical trials of absorbable hemostat (TDM-621)
  • 13 June 2019
    3-D Matrix appoints FUJIFILM Europe as their Europe-wide, exclusive distributor of PuraStat in Gastrointestinal endoscopic surgery indications
  • 23 January 2019
    Notice regarding the registration approval of PuraStat® in Canada for the absorbable hemostat.
  • 15 January 2019
    Partnership Agreement concluded with Vantage Endoscopy regarding sales and marketing of absorbable local hemostat "PuraStat®" in Canada
  • 20 November 2018
    [Delayed] Notice regarding the application for approval in the U.S. for PuraSINUS Gel(adhesion barrier and hemostatic material for the otorhinolaryngological field (ENT))
  • 10 May 2018
    Partnership Agreement concluded with DEMEDIC S.A. regarding sales and marketing of absorbable local hemostat "PuraStat®" in Argentina
  • 12 April 2017
    Partnership Agreement finalized with PENTAX Europe GmbH regarding sales and marketing of absorbable local hemostat“PuraStat®”in France, the Netherlands, and Portugal
  • 04 April 2017
    Execution of License Agreement for Hemostat in China
  • 28 April 2016
    Partnership Agreement concluded with Kaplan regarding sales and marketing of absorbable local hemostat "PuraStat®"in Chile
  • 05 April 2016
    [Delayed] Patent Granted for "Cardiac Tissue Regeneration" with Self-Assembling Peptide Technology in Japan
  • 22 February 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Mexico
  • 18 February 2016
    Partnership Agreement concluded with Genelife S.A regarding sales and marketing of absorbable local hemostat "PuraStat®" in Mexico
  • 15 February 2016
    Announcement of Change of Representative Directors
  • 10 February 2016
    Revision of Forecast of Financial Results for FY2015 and Extraordinary loss
  • 25 January 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Thailand
  • 22 January 2016
    Absorbable Hemostat PuraStat® Product Registration Obtained in Australia
  • 05 January 2016
    Patent granted on "3-D Cell Culture Scaffold" in Canada with self-assembling peptide technology exclusively licensed by MIT
  • 28 December 2015
    Partnership Agreement concluded with Transmedic Pte Ltd regarding sales and marketing of 「PuraStat®」in Singapore, Malaysia and Brunei
  • 04 November 2015
    Absorbable Hemostat "TDM-621" Product Registration Obtained in Brazil
  • 05 October 2015
    Partnership Agreement concluded with Maquet Australia Pty Ltd regarding sales and marketing of absorbable local hemostat 「PuraStat®」in Australia
  • 15 September 2015
    Patent Granted for "Transfection Agent (Agent for Transfer of Nucleic Acids into Cells)" Using the 3D-Matrix Peptide Technology
  • 23 July 2015
    Absorbable Hemostat "TDM-621" Product Registration Obtained in Colombia
  • 10 July 2015
    Partnership Agreement concluded with Daewoong Pharmaceutical Co., Ltd. regarding sales and marketing of absorbable local hemostat 「PuraStat®」in ASEAN
  • 7 July 2015
    Start of an Investigator-Initiated Clinical Trial for Treatment-Resistant Breast Cancer Patients with Novel siRNA Nucleic Acid Formulation “TDM-812” at the National Cancer Center
  • 27 May 2015
    Subsidiary Foundation in the Netherlands

Consolidated Financial Report

  • 15 December 2017
    CONSOLIDATED FINANCIAL REPORT For the Second Quarter of Fiscal Year Ending April 30, 2018 (Under Japan GAAP)
  • 02 October 2017
    CONSOLIDATED FINANCIAL REPORT For the First Quarter of Fiscal Year Ending April 30 2018 (Under Japan GAAP)
  • 15 March 2016
    CONSOLIDATED FINANCIAL REPORT For the Third Quarter of Fiscal Year Ending April 30, 2016 (Under Japan GAAP)
  • 15 December 2015
    CONSOLIDATED FINANCIAL REPORT For the Second Quarter of Fiscal Year Ending April 30, 2016
  • 7 September 2015
    For the First Quarter of Fiscal Year Ending April 30, 2016 (Under Japan GAAP)
  • 12 June 2015
    Consolidated Financial Report For the Fiscal Year Ended April 30, 2015 (Under Japan GAAP)

Most Recent Financial Statements

  •  

Mid-Term Business Plan

  • 21 December 2020
    Financial Results Briefing Second Quarter of FYE April 2021
  • 26 June 2019
    Financial results briefing for FYE April 2019
  • 14 June 2019
    Mid-term Business Plan (Fiscal Year Ending April 2020 to Fiscal Year Ending April 2022)
  • 19 December 2018
    Financial results briefing for the Second Quarter of FYE April 2019
  • 14 June 2018
    Mid-term Business Plan (Fiscal Year Ending April 2019 to Fiscal Year Ending April 2021)
  • 12 June 2015
    FY2015-FY2017 Mid-Term Business Plan

Other

  • 26 January 2016
    Business Analysis Report by Shared Research Inc.
  • 2 October 2015
    Business Analysis Report by Shared Research Inc.
  • 7 September 2015
    Business Analysis Report by Shared Research Inc.
  • 12 June 2015
    Business Analysis Report by Shared Research Inc.
IR Library  
Stock Information  
Stock Price Information  
IR Inquiries  
Disclaimer